<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hormonal contraception for menstrual suppression</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hormonal contraception for menstrual suppression</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hormonal contraception for menstrual suppression</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew M Kaunitz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Several available hormonal contraceptives can be used to reduce or eliminate monthly uterine bleeding. The safety and efficacy of these methods make them desirable for patients who have medical indications for suppression of menstruation, those for whom menstrual hygiene is challenging, and those who want the convenience of not having a monthly period.</p><p>Use of hormonal contraceptives for suppression of menstruation is reviewed here. Evaluation and management of patients with abnormal uterine bleeding, as well as general principles of contraceptive selection, are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "women" or "patients" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.</p><p class="headingAnchor" id="H1480649558"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Menstrual suppression involves the use of hormonal contraception to decrease the frequency and volume of normal menses or to suppress menses altogether (ie, achieve amenorrhea) [<a href="#rid1">1,2</a>]. Contraceptive options include combined estrogen-progestin oral pills, patches, or rings; progestin pills, injection, or implant; and levonorgestrel-releasing intrauterine devices (IUDs). In contrast to surgical procedures, such as endometrial ablation and hysterectomy, medical therapy does not irreversibly impair fertility. Menstrual suppression can be used to address medical conditions or for patient preferences regarding menses.</p><p class="headingAnchor" id="H2"><span class="h1">SAFETY OF MENSTRUAL SUPPRESSION</span><span class="headingEndMark"> — </span>Menstruation (ovulation followed by withdrawal bleeding) is not physiologically necessary for patients not wishing to conceive. In fact, most modern females experience many more menstrual cycles in their lifetimes than those in prior generations because of earlier menarche, fewer pregnancies, reduced duration of breastfeeding, and later menopause [<a href="#rid3">3</a>]. Moreover, this frequent, regular ovulation may actually increase a person's risk of some diseases, such as endometriosis and ovarian cancer. Studies worldwide have consistently reported that, among individuals informed that monthly bleeding is not necessary for their health, most favor bleeding frequency less often than monthly  (<a class="graphic graphic_table graphicRef63395" href="/z/d/graphic/63395.html" rel="external">table 1</a>) [<a href="#rid4">4-6</a>]. </p><p>The concept that monthly bleeding is healthy has been perpetuated by oral contraceptives (OCs) that were initially designed to mimic the average length of a normal menstrual cycle. This artificial "period" had no medical benefits, and the initial choice of 21/7 (monthly) OC formulations that result in withdrawal bleeding every four weeks was arbitrary.</p><p>Continuous or long-term use of estrogen-progestin (combination) or progestin-only contraception is associated with the same medical risks as cyclic use of these medications [<a href="#rid7">7</a>]. In contrast with patients on cyclic regimens, those using continuous-dose regimens benefit from reduction of menstrual symptoms (eg, headache, genital irritation, tiredness, bloating, and pain) [<a href="#rid8">8</a>]. We educate our patients that unscheduled bleeding is common during use of extended regimens.</p><p class="headingAnchor" id="H75035408"><span class="h1">COMMON INDICATIONS</span><span class="headingEndMark"> — </span>Suppression of menstruation can be beneficial for patients with an array of medical conditions and social needs  (<a class="graphic graphic_table graphicRef121605" href="/z/d/graphic/121605.html" rel="external">table 2</a>). The beneficial mechanisms include a reduction in the volume and frequency of uterine bleeding and/or a reduction in cyclic hormonal fluctuations.</p><p class="headingAnchor" id="H3"><span class="h2">Gynecologic</span><span class="headingEndMark"> — </span>Menstrual suppression can be helpful for a variety of gynecologic disorders  (<a class="graphic graphic_table graphicRef121605" href="/z/d/graphic/121605.html" rel="external">table 2</a>). We discuss the option of menstrual suppression with patients in the following situations, among others:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relief of dysmenorrhea</strong> – Dysmenorrhea refers to the recurrent, crampy, lower abdominal pain that occurs during menses. Dysmenorrhea may occur in the absence of disease (primary) or in response to another process, such as endometriosis (secondary). Menstrual suppression can relieve both.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5483.html" rel="external">"Dysmenorrhea in adult females: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of symptoms related to premenstrual hormone change or mood disorders</strong> – Examples include patients with breast pain, nausea, and gastrointestinal symptoms, as well as mood changes and premenstrual dysphoric disorder.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7381.html" rel="external">"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal uterine bleeding</strong> – Whether related to volume (eg, heavy menstrual bleeding) or frequency (eg, ovulatory disorders), menstrual suppression can reduce or eliminate abnormal uterine bleeding. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment of excessive bleeding related to uterine fibroids (leiomyoma) or adenomyosis</strong> – Some patients with heavy menstrual bleeding associated with leiomyomas respond to contraception that suppresses menstruation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">"Uterine fibroids (leiomyomas): Treatment overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of pain related to endometriosis</strong> – For patients whose endometriosis-related pain improves with hormonal contraception, continuous dosing regimens have been associated with more effective pain reduction. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Estrogen-progestin contraceptives'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction in risk of ovarian and endometrial cancers</strong> – While suppression of cyclic uterine bleeding does not directly impact the risk of ovarian and endometrial cancers, continuous use of combined hormonal contraceptives is associated with a substantially reduced risk of these malignancies, apparently because of their role in preventing ovulation and endometrial development. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Effects on cancer development'</a>.)</p><p></p><p class="headingAnchor" id="H3059804564"><span class="h2">Bleeding disorders</span><span class="headingEndMark"> — </span>Patients with bleeding disorders or chronic anemia, either hereditary or acquired  (<a class="graphic graphic_table graphicRef121605" href="/z/d/graphic/121605.html" rel="external">table 2</a>), may benefit from menstrual suppression. </p><p>Examples include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia (eg, due to immune thrombocytopenia [ITP], a primary platelet disorder)</p><p class="bulletIndent1"><span class="glyph">●</span>von Willebrand disease (VWD)</p><p class="bulletIndent1"><span class="glyph">●</span>Mild hemophilia or other clotting factor deficiency</p><p></p><p>Additional aspects of therapy are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery"</a> and  <a class="medical medical_review" href="/z/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B"</a> and  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>.)</p><p>Some patients treated with an anticoagulant or those with a period of thrombocytopenia related to cancer treatment or hematopoietic cell transplantation (HCT) may also benefit from menstrual suppression for a period of time. </p><p>Some patients with iron deficiency or anemia due to another condition may be less able to tolerate blood loss. Examples include hereditary hemorrhagic telangiectasia (HHT) or certain hemoglobinopathies (sickle cell disease, transfusion-dependent thalassemia). (See  <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions"</a>.)</p><p class="headingAnchor" id="H3897680791"><span class="h2">General medical</span><span class="headingEndMark"> — </span>Menstrual suppression can be helpful for individuals with a variety of medical conditions  (<a class="graphic graphic_table graphicRef121605" href="/z/d/graphic/121605.html" rel="external">table 2</a>). Menstrual suppression is particularly helpful for patients with severe anemia (hereditary or acquired) and conditions that are worsened by menses (eg, menstrual migraine). </p><p class="headingAnchor" id="H765578564"><span class="h2">Unique populations</span><span class="headingEndMark"> — </span>Suppression of menses can be particularly beneficial for individuals with the following issues:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescents</strong> – Young teens may benefit from reducing menstrual frequency. A reduction in menstrual frequency decreases dysmenorrhea and the inconvenience of menstruation during the school day when their access to pain relievers, sanitary pads or tampons, and a change of clothes may be limited [<a href="#rid9">9</a>]. Estrogen- and progestin-containing methods are options for patients who have experienced menarche [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/5847.html" rel="external">"Primary dysmenorrhea in adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a cognitive and/or physical disability that makes hygienic practice challenging</strong> – These patients may find menstrual bleeding emotionally upsetting or have difficulties with the use of menstrual hygiene products, such as patients with cerebral palsy or arthritis [<a href="#rid1">1,2,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with jobs/activities for which avoiding menses is beneficial </strong>– These situations apply to patients who are deployed for military duties or space flight, highly competitive athletes, or pursuing extended travel [<a href="#rid11">11-14</a>]. Avoidance of uterine bleeding and menstrual symptoms may also be particularly desirable during vacations, business travel, camping/wilderness experiences, special events, and academic examinations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gender-expansive patients</strong> – Patients may elect menstrual suppression to reduce gender dysphoria associated with menses [<a href="#rid2">2</a>]. An observational study of 530 transgender and gender-diverse (TGD) adolescents assigned female at birth reported nearly 25 percent were on menstrual suppression at first evaluation; the most common methods were combined oral contraceptive pills (46 percent), oral <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> (30 percent), and intramuscular depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (14.5 percent) [<a href="#rid15">15</a>]. Nearly 80 percent reported "very effective" levels of menstrual suppression and 86 percent reported overall satisfaction with menstrual suppression. Although none of the adolescents in this study used <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel IUDs</a>, some transgender individuals may choose this latter method to achieve menstrual suppression. While doses of testosterone used by transmasculine individuals may result in amenorrhea, this does not provide contraception. Patients capable of pregnancy are counseled about options for avoiding pregnancy, if applicable.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Cost savings</span><span class="headingEndMark"> — </span>A cost analysis comparing direct and indirect costs of monthly oral contraceptive cycles with an extended (trimonthly) cycle regimen reported lower annual costs with the latter [<a href="#rid16">16</a>]. Costs considered included those associated with oral contraceptive pills, hygienic products, pregnancy tests, analgesics, iron replacement therapy, visits to a clinician, and opportunity costs from missing time at work.</p><p class="headingAnchor" id="H1962063051"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Our approach is driven by the patient's baseline symptoms or medical indications for menstrual suppression, time available for onset of action, preference for reduction of menses versus amenorrhea, need for contraception, preferences for the route of administration, and potential side effects  (<a class="graphic graphic_algorithm graphicRef121669" href="/z/d/graphic/121669.html" rel="external">algorithm 1</a>). The choice of method strongly depends upon patient preferences, in addition to medical history and the side effect profiles of the options. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>We ask the following questions to help determine which choices may be most beneficial for any given patient and then follow the algorithm  (<a class="graphic graphic_algorithm graphicRef121669" href="/z/d/graphic/121669.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient a candidate for estrogen-containing products? (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Candidates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient medically require amenorrhea? For patients who do not, do they prefer amenorrhea or cyclic bleeding of a reduced volume?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who benefit from or prefer amenorrhea, how important is it to achieve complete amenorrhea?</p><p></p><p>We then counsel the patient about the available option(s) that are most likely to meet her goals. </p><p class="headingAnchor" id="H622199657"><span class="h1">TO ACHIEVE AMENORRHEA</span></p><p class="headingAnchor" id="H3578845716"><span class="h2">Combined estrogen-progestin methods</span><span class="headingEndMark"> — </span>Extended and continuous regimens of the oral pill and vaginal ring are safe and have few side effects [<a href="#rid8">8</a>]. We avoid continuous use of the transdermal contraceptive patch, releasing ethinyl estradiol and the progestin norelgestromin, because the overall ethinyl estradiol concentration is 60 percent higher in patch users compared with pill users. Concerns have been raised about possible increased risk of venous thromboembolism with extended use of this patch; however, supporting data are lacking [<a href="#rid17">17,18</a>]. An alternate transdermal contraceptive releases ethinyl estradiol and the progestin <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>. Because serum levels of ethinyl estradiol are substantially lower with this newer patch, it may be preferable if extended or continuous transdermal contraception is being considered [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches", section on 'Risk of venous thrombotic events'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended use</strong> – Patients using extended-use regimens take active hormone pills continuously for 28 days or more followed by periodic hormone-free intervals. Extended use regimens decrease the number and frequency of withdrawal bleeds per year. Common approaches involve having the patient use the placebo oral pills, or removing the one-year vaginal ring formulated with ethinyl estradiol and segesterone acetate, at three, four, or six-month intervals to experience a withdrawal bleed. The duration of contraceptive use is determined by the individual patient's preferences; the patient chooses when and how often hormone-free intervals occur and time them as needed for medical treatment, work, or other obligations. </p><p></p><p class="bulletIndent1">Commercial preparations of oral contraceptive pills with 91-day cycles are available  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 3</a>). Each oral pill pack contains 84 active tablets (ethinyl estradiol and <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> [LNG]) followed by seven placebo or 10 mcg ethinyl estradiol only pills. These formulations, available as generic medications, appear to provide both high contraceptive efficacy (failure rate 0.60 pregnancies per 100 women per year in a clinical trial) and endometrial safety [<a href="#rid20">20,21</a>]. </p><p></p><p class="bulletIndent1">Extended use of other combination pills (eg, ethinyl estradiol/<a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>) also appears to be safe and effective [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous use</strong> – Continuous use regimens have the patient use the oral pill or the one-year vaginal ring without a placebo or removal week for a continuous year. The three-week ring formulated with ethinyl estradiol and etonogestrel can also be used for four weeks, removed, and a new ring inserted. Thus, hormone-free intervals are eliminated, and the patient has no scheduled withdrawal bleeding. Data on continuous use of the vaginal ring are limited but suggest reductions in bleeding and spotting days similar to that of extended pill regimens [<a href="#rid24">24-26</a>]. </p><p></p><p>Both extended use and continuous use regimens for each contraceptive method are discussed in related topics. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Continuous or extended use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings", section on 'Insertion and use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches", section on 'Extended cycle use'</a>.)</p><p></p><p>Unscheduled bleeding/spotting often occurs during the first few months of extended or continuous oral contraceptive use but then resolves. If troublesome unscheduled bleeding occurs after the first 21 days of hormone use, one approach is to stop the oral contraceptive for three days to allow withdrawal bleeding and then resume the method for at least 21 days of continuous use [<a href="#rid22">22</a>]. This approach of scheduling a short hormone-free interval can be repeated whenever bothersome breakthrough bleeding occurs, as long as the patient has taken at least 21 days of active contraceptive continuously before proceeding with a hormone-free interval. Over time, breakthrough bleeding episodes will become spaced out and stop. (See  <a class="medical medical_review" href="/z/d/html/5474.html" rel="external">"Evaluation and management of unscheduled bleeding in individuals using hormonal contraception"</a>.)</p><p class="headingAnchor" id="H1504781398"><span class="h2">Progestin-only methods</span></p><p class="headingAnchor" id="H876664911"><span class="h3">First tier</span></p><p class="headingAnchor" id="H2976628840"><span class="h4">Depot medroxyprogesterone acetate</span><span class="headingEndMark"> — </span>Depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) inhibits ovulation and reduces or eliminates uterine bleeding. Fifty to 75 percent of patients who use DMPA for one year experience amenorrhea, which becomes more common as the duration of use increases [<a href="#rid27">27</a>]. Thus, prolonged use of this agent enhances reduction of menstruation-related symptoms. DMPA is given by intramuscular or subcutaneous (formulations differ by intended route) injection at 90-day intervals. DMPA use is discussed in detail in separate topics. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Menstrual changes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a> is a good choice for inducing amenorrhea in patients in whom estrogen-progestin contraceptives or a LNG-releasing intrauterine device (LNG 52 mg IUD) is either contraindicated, causes additional health concerns, or is not desired by the patient. Initial irregular bleeding is the most common adverse effect. Additional adverse effects, such as acne or other skin problems (related to its androgenicity), headache, and depression, resulted in discontinuation by three years in approximately 70 percent of patients in one trial [<a href="#rid28">28</a>]. Although use of DMPA reduces bone mineral density, bone loss is mostly reversed after cessation of therapy. DMPA use is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'</a>.)</p><p>Return of fertility upon discontinuation of contraceptive injections may be delayed compared with other methods. (See  <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration", section on 'Return to fertility after discontinuation'</a>.)</p><p>For individuals who choose not to use intramuscular or subcutaneous injections because of concern for bleeding or infection, <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate (NETA) becomes a first-tier treatment option. Such patients may include those with thrombocytopenia or neutropenia. (See <a class="local">'Norethindrone acetate'</a> below.)</p><p class="headingAnchor" id="H704530133"><span class="h4">Levonorgestrel intrauterine device (LNG 52 mg)</span><span class="headingEndMark"> — </span>The LNG 52 mg IUDs are the best studied progestin-only modality for reducing the frequency and volume of menstrual blood loss. As an example, after one year of use, amenorrhea is reported by approximately 20 percent of LNG 52 mg IUD users compared with 6 percent of LNG 13.5 users [<a href="#rid29">29-31</a>]. At the end of two years of use, 30 to 50 percent of LNG 52 users reported amenorrhea compared with 12 percent of patients using the LNG 13.5 [<a href="#rid31">31,32</a>]. Therefore, patients who prefer to avoid menstrual bleeding may benefit from a 52 mg device. However, as with <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a>, the time to achieve amenorrhea may take a year or more. A detailed discussion of the LNG doses, efficacy, duration of use, and amenorrhea rates for the various <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> is presented separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Devices and characteristics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel-releasing IUDs'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> are a good choice for reducing uterine bleeding in patients with hemostatic disorders and patients who cannot use, or prefer to avoid, estrogen-containing methods [<a href="#rid33">33</a>]. Because ovulation-related bleeding along with heavy menses is a concern for some patients with hemostatic disorders, in selected patients, concomitant use of an LNG IUD and combination oral contraceptive, oral <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate, or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a> may be helpful [<a href="#rid34">34</a>]. In addition, clinicians should be aware that when a LNG 52 mg IUD is used to control heavy menstrual bleeding (HMB), including in patients with bleeding disorders, suppression of menstruation may stop prior to the six-year replacement time. When this occurs, patients may benefit from early replacement of the IUD [<a href="#rid35">35</a>]. A detailed discussion of use of the LNG IUD in patients with HMB or anovulatory bleeding can be found separately. (See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Levonorgestrel intrauterine device'</a>.)</p><p>As the lower dose <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> do not typically result in amenorrhea, we do not use them for this indication. However, they can be helpful for patients who wish to maintain cyclic withdrawal bleeding of a reduced volume. (See <a class="local">'Levonorgestrel intrauterine device (LNG 19.5 mg)'</a> below.)</p><p class="headingAnchor" id="H3770257214"><span class="h3">Second tier</span></p><p class="headingAnchor" id="H623734935"><span class="h4">Norethindrone acetate</span><span class="headingEndMark"> — </span>Oral NETA (5 mg tablets taken orally three times daily) also reduces menstrual bleeding [<a href="#rid36">36</a>]. In one study including 22 patients with HMB who received cyclical NETA therapy, blood loss was reduced by 87 percent in patients with idiopathic HMB [<a href="#rid36">36</a>]. However, none of these patients experienced amenorrhea during the three-month study period, and only an approximate one-quarter elected to continue with the treatment once the study ended. When compared with the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUD</a>, the two therapies produced an equivalent reduction in menstrual blood loss, but patient satisfaction was much higher with the IUD (76 versus 22 percent after three cycles).</p><p>In our experience, a lower dose of NETA (5 mg orally daily) reduces blood loss and often results in amenorrhea when taken continuously in patients suffering from HMB, including those with uterine fibroids or anovulatory uterine bleeding. We find that continuous, rather than cyclic, use of NETA is most effective in reducing or eliminating HMB and represents an easier regimen for compliance. Unfortunately, clinical trial data have not addressed continuous use of NETA in patients with HMB. However, a study assessing six months of continuous NETA 2.5 mg daily in women with endometriosis reported that 94 percent (84/89) of participants became amenorrheic [<a href="#rid37">37</a>]. Clinically, we find that the use of NETA is limited by its adverse effects including unpleasant mood symptoms, increased appetite, and bloating. Reducing the dose of NETA may reduce these side effects. In our experience, some patients who have achieved satisfactory menstrual suppression with 5 mg of NETA daily successfully transition to 2.5 mg daily (cutting the 5 mg tablets in half). However, other patients attempting to lower the dose may experience an increase in bleeding or spotting, which responds to restoring the initial higher dose of NETA. Even though it is available as a generic formulation, NETA is typically more costly than oral contraceptives or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a>.</p><p>Of note, 5 mg or 2.5 mg of NETA represents a dose higher than that required for contraception. For example, commonly used estrogen-progestin contraceptives contain NETA 1 mg daily. The dose is also substantially higher than that of the <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> 0.35 mg progestin-only contraceptive pill, which is not typically used for this indication, as unscheduled bleeding is much more common than amenorrhea. (See  <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H15"><span class="h4">Etonogestrel implant</span><span class="headingEndMark"> — </span>The etonogestrel-progestin implant is less satisfactory for suppression of menstruation than the other methods discussed above. During the first two years of use of the single-rod <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">etonogestrel implant</a> (commercial name Nexplanon), 22 percent of patients developed amenorrhea, 34 percent had fewer than three bleeding/spotting episodes in 90 days, and the remainder had frequent or prolonged episodes of uterine bleeding [<a href="#rid38">38</a>]. However, the etonogestrel implant can be a good option for patients who desire a highly reliable long-acting progestin-only contraceptive and are willing to accept an approximately 50 percent likelihood of reduced bleeding. In contrast with patients using LNG 52 mg IUDs or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a> injections, amenorrhea does not increase with ongoing duration of implant use. The implant is approved for up to three years of contraception, although studies support its efficacy through five years [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p class="headingAnchor" id="H2196494888"><span class="h2">GnRH analogues</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH agonists</strong> – Gonadotropin-releasing hormone (GnRH) agonists include <a class="drug drug_general" data-topicid="9673" href="/z/d/drug information/9673.html" rel="external">nafarelin</a>, <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a>, <a class="drug drug_general" data-topicid="8867" href="/z/d/drug information/8867.html" rel="external">buserelin</a>, <a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a>, and <a class="drug drug_general" data-topicid="10018" href="/z/d/drug information/10018.html" rel="external">triptorelin</a>. Agonists, typically given as leuprolide, eliminate menstruation by suppressing GnRH pulsatility from the pituitary. However, use of GnRH agonists is limited for menstrual suppression in the absence of other clinical indications such as medical need for amenorrhea or endometriosis-related pain, because of the resultant menopausal side effects. However, for patients who benefit from rapid induction of amenorrhea, such as those about to receive chemotherapeutic agents or undergo bone marrow transplant, GnRH agonists will be effective in approximately one menstrual cycle. Other indications for GnRH agonists include preoperative treatment of anemic patients when surgery is planned for leiomyoma (ie, uterine fibroids). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH antagonists</strong> – The oral GnRH antagonists <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a> and relugolix are indicated for the treatment of pain associated with endometriosis. However, because the incidence of amenorrhea associated with these medications is &lt;10 percent, GnRH antagonists are not recommended when the goal is achieving amenorrhea [<a href="#rid41">41,42</a>]. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain"</a>.) </p><p></p><p>Endometriosis is a separate indication for use of GnRH analogues, and the pharmacology, side effects, and need for add-back therapy are presented in that topic review. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists"</a>.)</p><p class="headingAnchor" id="H1084721979"><span class="h1">FOR REDUCTION OF CYCLIC WITHDRAWAL BLEEDING</span></p><p class="headingAnchor" id="H2492672534"><span class="h2">Cyclic estrogen-progestin methods</span><span class="headingEndMark"> — </span>Cyclic use of estrogen-progestin contraceptives (oral pills, transdermal patch, and vaginal ring) is a reasonable first-line therapy if the goal is reduction, but not necessarily elimination, of monthly blood flow and there are no contraindications to estrogen administration (eg, previous thromboembolic event or stroke, history of an estrogen-dependent tumor, ≥35 years of age and a cigarette smoker, active severe liver disease, undiagnosed abnormal uterine bleeding). (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p>Regardless of formulation, cyclic dosing regimens typically involve three weeks of exposure to the combined estrogen-progestin followed by a week of no exposure (achieved with oral pill placebo tablets or removal of the ring or patch). With cyclic dosing, regular withdrawal bleeding still occurs, although the amount of blood loss is significantly reduced, and some will still experience menstrual symptoms during the hormone-free interval [<a href="#rid43">43,44</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Administration and use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches", section on 'Administration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings", section on 'Administration and use'</a>.)</p><p></p><p>For patients who desire oral pills, shortening the hormone-free interval from the traditional seven to fewer days of placebo or use of low-dose estrogen during the traditional hormone-free week provides greater ovarian suppression, which may help reduce both the occurrence of symptoms associated with hormone withdrawal and the risk of pregnancy [<a href="#rid45">45</a>]. Withdrawal spotting/bleeding may occur during pill-free intervals. Several 28-day oral contraceptive formulations, which include a shortened hormone-free interval, are available (these can be referred to as 24/4 oral contraceptive formulations)  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 3</a>).</p><p>For the transdermal patch, the volume of withdrawal bleeding is reduced to a level similar to that of the estrogen-progestin pills. Unscheduled bleeding is common in the first months of use but then subsides. Cyclic use of the vaginal ring results in cycle control that is at least as good as that of the estrogen-progestin pills and transdermal patch.</p><p>Patients who suffer from menstrual symptoms with cyclic dosing or who have medical indications or preferences for no bleeding may benefit from an extended or continuous dose regimen. (See <a class="local">'Combined estrogen-progestin methods'</a> above.)</p><p class="headingAnchor" id="H2969308540"><span class="h2">Levonorgestrel intrauterine device (LNG 19.5 mg)</span><span class="headingEndMark"> — </span>The lower <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> release rate in the levonorgestrel 19.5 mg intrauterine device (LNG 19.5 IUD; commercial name Kyleena) is a highly effective contraceptive that also reduces the volume of withdrawal bleeding. While it can result in amenorrhea in approximately 12 percent of users by one year, this rate is approximately one-half that for the LNG 52 mg IUDs [<a href="#rid46">46</a>]. As the LNG 19.5 mg IUD is approved for up to five years of use, we prefer this device to the LNG 13.5 mg IUD (commercial name Skyla), which also reduces the volume of withdrawal bleeding but is only approved for contraception for up to three years. Discussion of the various IUD devices and impact on bleeding patterns is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">OTHER</span><span class="headingEndMark"> — </span>Medications other than contraceptives and gonadotropin-releasing hormone agonists can be used to suppress menstruation. These are generally used when there is a specific medical indication for the approaches below compared with the more commonly used approaches above. Some of these drugs may not universally suppress ovulation; therefore, an additional contraceptive method may be necessary (eg, male or female condoms), and ovulation-related symptoms may not subside. Some examples are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postmenopausal hormone therapy</strong> – A postmenopausal estrogen-progestin formulation can be used off-label to suppress menstruation. This is oral ethinyl estradiol (EE) 5 mcg combined with <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate (NETA) 1 mg (available as a 28-day continuous formulation; eg, Jinteli 1/5 and other generics [<a href="#rid47">47</a>]), which is which is labeled for treatment of menopausal symptoms. Because of its low estrogen dose, some clinicians prescribe this 1/5 menopausal formulation off-label to premenopausal patients desiring menstrual suppression when lower estrogen doses are preferred, such as for females &gt;35 years of age who are obese, have controlled hypertension, smoke cigarettes, or have migraines without aura. While not studied expressly for this purpose, the lower estrogen dose, as compared with that in oral contraceptive pills, is believed to have a reduced risk of thromboembolic events. (See  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p></p><p class="bulletIndent1">Many premenopausal users develop amenorrhea during use of this 1/5 formulation. Because the dose of NETA is lower, this EE/NETA formulation likely causes fewer undesirable progestin-related side effects than NETA 5 mg tablets. Although the 1 mg dose of NETA is sufficient to prevent ovulation (and, in fact, is higher than the dose in some marketed oral contraceptives), this 1/5 formulation is not approved for use as a contraceptive, and consistent back-up contraception (eg, condom use) should be advised if this formulation is prescribed to patients who need birth control. (See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Role of noncontraceptive estrogen-progestin formulations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">Danazol</a> – Danazol suppresses pituitary output of follicle-stimulating hormone and luteinizing hormone, which leads to atrophy of endometrial tissue. However, androgenic side effects, such as acne, hirsutism, and deepening voice, limit its use. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Danazol'</a>.)</p><p></p><p class="headingAnchor" id="H60650653"><span class="h1">IMPACT ON FERTILITY</span><span class="headingEndMark"> — </span>After contraceptive cessation, patients who use hormonal contraceptives continuously or long term do not appear to have reduced fecundity compared with patients using nonhormonal methods. While there may be a brief delay in conception for patients who stop hormonal contraceptives compared with patients discontinuing nonhormonal methods, the reported 12-month conception rates are similar. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Return of menses after stopping'</a>.)</p><p>The only hormonal contraceptive associated with an extended impact on fertility is depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>. (See  <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a>.)</p><p class="headingAnchor" id="H969409569"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for menstrual suppression</strong> – Suppression of menstruation has medical and personal benefits for many patients and is cost-effective. Menstruation (ovulation followed by withdrawal bleeding) is not physiologically necessary. (See <a class="local">'Gynecologic'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction of menstrual volume</strong> – For patients whose goal is reduction, but not necessarily elimination, of monthly blood flow, we suggest cyclic use of estrogen-progestin contraceptives rather than progestins or continuous use of combined hormonal preparations (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Users of the estrogen-progestin pill, transdermal patch, or vaginal ring should not have any contraindications to use of contraceptive doses of estrogen. (See <a class="local">'Cyclic estrogen-progestin methods'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amenorrhea</strong> – For patients whose goal is amenorrhea, depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA), continuous combined estrogen-progestin contraceptives, and <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) 52 mg intrauterine device are all effective. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although randomized trials comparing these drugs have not been performed, <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a> appears to have the highest rate of amenorrhea, while the LNG 52 mg intrauterine device (IUD) is the most convenient and appears to be associated with higher continuation rates and fewer bothersome side effects than progestin injections. For these reasons, many patients select the IUD. (See <a class="local">'Depot medroxyprogesterone acetate'</a> above and <a class="local">'Combined estrogen-progestin methods'</a> above and <a class="local">'Levonorgestrel intrauterine device (LNG 52 mg)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who desire amenorrhea, need to avoid estrogen, and prefer a long-acting reversible contraceptive, we suggest the LNG 52 mg IUD or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a> rather than the progestin-releasing implant (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer the IUD and progestin injections for these patients as rates of amenorrhea are higher compared with the implant. (See <a class="local">'Levonorgestrel intrauterine device (LNG 52 mg)'</a> above and <a class="local">'Depot medroxyprogesterone acetate'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Altshuler AL, Hillard PJ. Menstrual suppression for adolescents. Curr Opin Obstet Gynecol 2014; 26:323.</a></li><li><a class="nounderline abstract_t">ACOG Clinical Consensus No. 3: General Approaches to Medical Management of Menstrual Suppression. Obstet Gynecol 2022; 140:528.</a></li><li><a class="nounderline abstract_t">Lin K, Barnhart K. The clinical rationale for menses-free contraception. J Womens Health (Larchmt) 2007; 16:1171.</a></li><li><a class="nounderline abstract_t">den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59:357.</a></li><li><a class="nounderline abstract_t">Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004; 70:359.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186:1142.</a></li><li><a class="nounderline abstract_t">Jacobson JC, Likis FE, Murphy PA. Extended and continuous combined contraceptive regimens for menstrual suppression. J Midwifery Womens Health 2012; 57:585.</a></li><li><a class="nounderline abstract_t">Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 2014; :CD004695.</a></li><li><a class="nounderline abstract_t">Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104:936.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion No. 448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol 2009; 114:1428.</a></li><li><a class="nounderline abstract_t">Schneider MB, Fisher M, Friedman SB, et al. Menstrual and premenstrual issues in female military cadets: a unique population with significant concerns. J Pediatr Adolesc Gynecol 1999; 12:195.</a></li><li><a class="nounderline abstract_t">Frankovich RJ, Lebrun CM. Menstrual cycle, contraception, and performance. Clin Sports Med 2000; 19:251.</a></li><li><a class="nounderline abstract_t">Jain V, Wotring V. Medically induced amenorrhea in female astronauts. NPJ Microgravity 2016.</a></li><li><a class="nounderline abstract_t">Eagan SM. Menstrual Suppression for Military Women: Barriers to Care in the United States. Obstet Gynecol 2019; 134:72.</a></li><li><a class="nounderline abstract_t">Moussaoui D, O'Connell MA, Elder CV, et al. Characteristics of Menstrual Suppression and Its Association With Mental Health in Transgender Adolescents. Obstet Gynecol 2023; 142:1096.</a></li><li><a class="nounderline abstract_t">Braunstein JB, Hausfeld J, Hausfeld J, London A. Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens. Obstet Gynecol 2003; 102:699.</a></li><li><a class="nounderline abstract_t">van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168.</a></li><li><a class="nounderline abstract_t">Devineni D, Skee D, Vaccaro N, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 2007; 47:497.</a></li><li><a class="nounderline abstract_t">Nelson AL, Kaunitz AM, Kroll R, et al. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results. Contraception 2021; 103:137.</a></li><li><a class="nounderline abstract_t">Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89.</a></li><li><a class="nounderline abstract_t">Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006; 195:92.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006; 195:935.</a></li><li><a class="nounderline abstract_t">Machado RB, de Melo NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception 2010; 81:215.</a></li><li><a class="nounderline abstract_t">Miller L, Verhoeven CH, Hout Ji. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005; 106:473.</a></li><li><a class="nounderline abstract_t">Guazzelli CA, Barreiros FA, Barbosa R, et al. Extended regimens of the vaginal contraceptive ring: cycle control. Contraception 2009; 80:430.</a></li><li><a class="nounderline abstract_t">Barreiros FA, Guazzelli CA, Barbosa R, et al. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contraception 2010; 81:223.</a></li><li class="breakAll">Depo-provera- medroxyprogesterone acetate injection, suspension. US Food and Drug Administration (FDA) approved product information. Revised February 2019. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on June 13, 2019).</li><li><a class="nounderline abstract_t">Diedrich JT, Zhao Q, Madden T, et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol 2015; 213:662.e1.</a></li><li class="breakAll">Mirena package insert. http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf (Accessed on June 12, 2017).</li><li class="breakAll">Liletta package insert. http://pi.actavis.com/data_stream.asp?product_group=1960&amp;p=pi&amp;language=E (Accessed on April 24, 2015).</li><li class="breakAll">Skyla package insert. http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf (Accessed on April 24, 2015).</li><li><a class="nounderline abstract_t">Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129.</a></li><li><a class="nounderline abstract_t">Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008; 90:673.</a></li><li><a class="nounderline abstract_t">Kadir RA, Chi C. Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy. Contraception 2007; 75:S123.</a></li><li><a class="nounderline abstract_t">Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception 2011; 83:242.</a></li><li><a class="nounderline abstract_t">Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105:592.</a></li><li><a class="nounderline abstract_t">Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 2016; 105:734.</a></li><li class="breakAll">Nexplanon- etonogestrel implant. US Food and Drug Administration (FDA) approved product information. Revised October, 2018. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on June 13, 2019).</li><li><a class="nounderline abstract_t">McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol 2017.</a></li><li><a class="nounderline abstract_t">Ali M, Akin A, Bahamondes L, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod 2016; 31:2491.</a></li><li><a class="nounderline abstract_t">Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med 2017; 377:28.</a></li><li><a class="nounderline abstract_t">Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet 2022; 399:2267.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95:261.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89:179.</a></li><li><a class="nounderline abstract_t">Fels H, Steward R, Melamed A, et al. Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives. Contraception 2013; 87:732.</a></li><li class="breakAll">Kyleena- levonorgestrel intrauterine device.. US Food and Drug Administration (FDA) approved product information. Revised March, 2018.. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on June 26, 2019).</li><li><a class="nounderline abstract_t">Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators. Obstet Gynecol 2000; 96:366.</a></li></ol></div><div id="topicVersionRevision">Topic 5423 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25110977" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Menstrual suppression for adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ACOG Clinical Consensus No. 3: General Approaches to Medical Management of Menstrual Suppression</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17937570" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The clinical rationale for menses-free contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10518229" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504373" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12066088" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217068" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Extended and continuous combined contraceptive regimens for menstrual suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25072731" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506238" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20134299" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACOG Committee Opinion No. 448: Menstrual manipulation for adolescents with disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10584223" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Menstrual and premenstrual issues in female military cadets: a unique population with significant concerns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10740758" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Menstrual cycle, contraception, and performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : medically induced amenorrhea in female astronauts</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31188318" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Menstrual Suppression for Military Women: Barriers to Care in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37562053" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characteristics of Menstrual Suppression and Its Association With Mental Health in Transgender Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14550999" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102549" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389559" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33259782" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12954519" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A multicenter, randomized study of an extended cycle oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813747" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647684" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159177" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135576" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Extended regimens of the contraceptive vaginal ring: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19835716" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Extended regimens of the vaginal contraceptive ring: cycle control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159178" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159178" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26259905" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Three-year continuation of reversible contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26259905" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Three-year continuation of reversible contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26259905" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Three-year continuation of reversible contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26259905" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Three-year continuation of reversible contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11927115" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18001734" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531603" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310286" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647148" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677792" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677792" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28147241" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27671673" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28525302" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35717987" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10674591" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hormone withdrawal symptoms in oral contraceptive users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9015017" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352800" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352800" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10960627" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
